ChemoCentryx

FDA Building 2
Biotech

AdComm experts split on whether to OK ChemoCentryx's avacopan

Ten experts voted that the benefit-risk profile supports approval, while the other eight voted against authorizing the rare disease drug.
Nick Paul Taylor May 7, 2021 6:47am
FDA Building 2

ChemoCentryx's stock sinks as FDA flags issues with pivotal data

May 5, 2021 8:25am
European Union flags waving in front of the EU Parliament building in Brussels

ChemoCentryx pulls conditional approval filing

Jan 24, 2019 9:40am
Pancreatic cancer

ChemoCentryx eyes combinations after posting pancreatic cancer OS data 

Jan 23, 2018 8:05am
Zurich Switzerland

Vifor flies solo, plans spending spree as sister unit files IPO

Apr 7, 2017 2:38am
Spotlight

$85M windfall for PhIII licensing deal sparks a rally for ChemoCentryx

May 11, 2016 7:39am